Markets:

Overview

News

Currencies

International

Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.7214 +0.0303 (+4.38%)

Streaming Delayed Price Updated: 10:09 AM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

5 Value Stocks In The Healthcare Sector ↗

December 26, 2022

Via Benzinga

Humacyte's Return on Invested Capital Insights ↗

December 19, 2022

Via Benzinga

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime

December 13, 2022

Thursday, December 15, 2022 @ 8:00 AM ET

From Humacyte, Inc

Via GlobeNewswire

Sidoti's December Small-Cap Virtual Conference

December 06, 2022

Via ACCESSWIRE

Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022

December 01, 2022

Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference

From Humacyte, Inc

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

December 14, 2022

On Wednesday, 115 stocks hit new 52-week lows.

Via Benzinga

Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference

November 23, 2022

From Humacyte, Inc

Via GlobeNewswire

Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday ↗

November 21, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 15, 2022

On Tuesday, 34 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 16, 2022

On Wednesday, 70 companies set new 52-week lows.

Via Benzinga

Humacyte Third Quarter 2022 Financial Results and Business Update

November 10, 2022

From Humacyte, Inc

Via GlobeNewswire

Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting

November 07, 2022

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022

November 03, 2022

From Humacyte, Inc

Via GlobeNewswire

Livent, Amgen And Some Other Big Stocks Moving Lower On Monday ↗

September 12, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Humacyte Earnings Perspective: Return On Invested Capital ↗

September 09, 2022

According to Benzinga Pro, during Q2, Humacyte (NASDAQ:HUMA) earned $36.87 million, a 285.9% increase from the preceding quarter. Humacyte also posted a total of $1.30 million in sales, a 458.37%...

Via Benzinga

Earnings Scheduled For August 12, 2022 ↗

August 12, 2022

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 06, 2022

Via Benzinga

41 Stocks Moving In Monday's Mid-Day Session ↗

May 16, 2022

Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

95 Biggest Movers From Yesterday ↗

June 07, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II...

Via Benzinga

52 Stocks Moving In Monday's Mid-Day Session ↗

June 06, 2022

Gainers DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users.

Via Benzinga

Earnings Scheduled For May 13, 2022 ↗

May 13, 2022

Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million.

Via Benzinga

73 Biggest Movers From Yesterday ↗

May 17, 2022

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 19, 2022

Gainers

Via Benzinga

Humacyte's Return On Capital Employed Insights ↗

March 30, 2022

Pulled from Benzinga Pro data, Humacyte (NASDAQ:HUMA) posted Q4 earnings of $42.59 million, an increase from Q3 of 234.92%. Sales dropped to $177.00 thousand, a 26.56% decrease between quarters.

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

How To Attend Humacyte Q4 2021 Earnings Conference Call ↗

March 22, 2022

Humacyte (NASDAQ:HUMA) will host a conference call at 08:00 AM ET on March 29, 2022, to discuss Q4 2021 earnings results. How to Attend Humacyte (HUMA) Conference Call Follow this...

Via Benzinga

Humacyte's Human Acellular Vessel Shows Long Term Benefit In Hemodialysis Patients ↗

February 28, 2022

Humacyte Inc (NASDAQ: HUMA) announced five-year data from a Phase 2 trial of Human Acellular Vessel (HAV) for arteriovenous (AV) access in hemodialysis. In the...

Via Benzinga

Earnings Scheduled For March 29, 2022 ↗

March 29, 2022

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.